|
EP3706730A1
|
|
Edasalonexent dosing regimen for treating muscular dystrophy
|
|
US2017342046A1
|
|
Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders
|
|
WO2016086136A1
|
|
Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
|
|
CN107205994A
|
|
Aliphatic acid cysteamine conjugate and their purposes as the activator of autophagy
|
|
US2016083336A1
|
|
Fatty acid acylated salicylates and their uses
|
|
USRE46608E
|
|
Fatty acid niacin conjugates and their uses
|
|
CN105916378A
|
|
Fatty acid niacin conjugates
|
|
CN105917730A
|
|
Access point assisted spatial reuse
|
|
WO2014204856A1
|
|
Fatty acid anticancer derivatives and their uses
|
|
US2014288025A1
|
|
Fatty acid antiviral conjugates and their uses
|
|
CA2896776A1
|
|
Use of fatty acid niacin conjugates for treating diseases
|
|
CA2874244A1
|
|
Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
|
MX2014013150A
|
|
Fatty acid conjugates of statin and fxr agonists; compositions and method of uses.
|
|
US2013244966A1
|
|
Fatty acid antiviral conjugates and their uses
|
|
WO2012154554A1
|
|
Fatty acid triterpene derivatives and their uses
|
|
WO2012154564A1
|
|
Fatty acid phenolic derivatives and their uses
|
|
EP2701509A1
|
|
Fatty acid guanidine and salicylate guanidine derivatives and their uses
|
|
CN103648490A
|
|
Use of intracellular enzymes for the release of covalently linked bioactives
|
|
WO2012161798A1
|
|
Fatty acid gamma aminobutyric acid (gaba) conjugates and their uses
|
|
WO2012115695A1
|
|
Bis-fatty acid conjugates and their uses
|
